

Important Safety Information (cont'd)

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

The most commonly reported adverse reactions ($\geq 10\%$) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or https://www.pfizersafetyreporting.com or VAERS at 1-800-822-7967 or http://vaers.hhs.gov

Please see accompanying COMIRNATY Full Prescribing Information.





Manufactured for BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz, Germany Marketing Authorization Holder

Manufactured by Pfizer Inc. New York, NY 10017

PP-CVV-USA-2792 © 2023 Pfizer Inc. All rights reserved. September 2023

Dear Healthcare Professional:

The attached sheets are provided as an option to remind the caregivers of eligible pediatric patients 12 years of age and older or eligible adult patients that you have recommended they visit a local pharmacy to receive COVID-19 vaccination with COMIRNATY® (COVID-19 Vaccine, mRNA) 2023-2024 Formula.

Please use at your discretion.



INDICATION

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

Important Safety Information

Do not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Continued on next page.

Please see additional Important Safety Information on next page.

Before administration of the vaccine, please see accompanying Full Prescribing Information in pocket or visit <u>cvdvaccine-us.com</u>.



Important Safety Information (cont'd)

Management of Acute Allergic Reactions

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

The Centers for Disease Control and Prevention (CDC) has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Continued on back cover.

Please see additional Important Safety Information on reverse side.

Before administration of the vaccine, please see accompanying Full Prescribing Information in pocket or visit cvdvaccine-us.com.

OFFICE STAMP HERE

Date _____



(COVID-19 Vaccine, mRNA)

This is a reminder that I recommend a visit to a local pharmacy to receive COMIRNATY® (COVID-19 Vaccine, mRNA) 2023-2024 Formula.

This is not a prescription.

Find and schedule an appointment at a pharmacy or doctor's office that offers COMIRNATY 2023-2024 Formula by **scanning the QR code to the right**. Just enter your zip code and select "Ages 12 Years & Older."







Manufactured for BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz, Germany Marketing Authorization Holder

Manufactured by Pfizer Inc. New York, NY 10017